SCHEMBL4608038

SCHEMBL4608038

OCC1(c2ccccc2Br)CCCC1

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.41
ALOX15 P16050 1/20 0.39
SLC6A2 P23975 3/20 0.38
SLC6A3 Q01959 3/20 0.38
SLC6A4 P31645 2/20 0.38
DPP4 P27487 1/20 0.37
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37
HDAC4 P56524 4/20 0.36
PDE7A Q13946 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
NPSR1 Q6W5P4 1/20 0.35
ALDH1A1 P00352 1/20 0.35
POLB P06746 1/20 0.35
MAPK1 P28482 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31583077 0.84 ALDH1A1 (0.37) ALOX15HTR2AHTR2CL3MBTL1ALDH1A1
SCHEMBL31116706 0.81 SLC6A3 (0.57) SLC6A2SLC6A3SLC6A4DPP4HTR2A
SCHEMBL28013086 0.79 SLC6A3 (0.44) LMNASLC6A2SLC6A3SLC6A4DPP4
SCHEMBL28015330 0.77 SLC6A3 (0.39) LMNASLC6A2SLC6A3SLC6A4DPP4
SCHEMBL11681179 0.76 HDAC4 (0.47) LMNAALOX15SLC6A2SLC6A3SLC6A4
SCHEMBL27631594 0.75 MEN1 (0.38) LMNASLC6A2SLC6A3SLC6A4DPP4
SCHEMBL15862743 0.74 SLC6A3 (0.68) ALOX15SLC6A2SLC6A3SLC6A4NPSR1
SCHEMBL5500843 0.74 CA2 (0.39) LMNAALOX15SLC6A2SLC6A3SLC6A4
SCHEMBL28168405 0.74 CETP (0.38) SLC6A2SLC6A3SLC6A4HDAC4
SCHEMBL23649271 0.74 OPRL1 (0.40) HTR2AHTR2CHDAC4PDE7A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1246797-B1 CYCLOPENTYL SULFONAMIDE DERIVATIVES LILLY CO ELI (US) 2008-07-23 EP disclosed
EP-1390072-A2 USE OF AN AMPA RECEPTOR POTENTIATOR FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF TYPE 2 DIABETES ELI LILLY AND COMPANY (US) 2004-02-25 EP disclosed
US-6639107-B1 Potentiating glutamate receptor function ELI LILLY AND COMPANY 2003-10-28 US disclosed
WO-2002089848-A2 USE OF AN AMPA RECEPTOR POTENTIATOR FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF TYPE 2 DIABETES ELI LILLY AND COMPANY (US) 2002-11-14 WO disclosed
EP-1246797-A1 CYCLOPENTYL SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-10-09 EP disclosed
WO-2001042203-A1 CYCLOPENTYL SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2001-06-14 WO disclosed